ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
AI-Designed mRNA vaccine takes on advanced tumors in first human test
⭐️ VACCINE ⭐️ Recruiting nowThis early-phase trial tests a new mRNA vaccine called PAN-NeoVax, designed by artificial intelligence to target multiple cancer types. The vaccine is injected directly into tumors in 9 patients with advanced solid cancers who have run out of standard options. The main goal is to…
Matched conditions: ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: West China Hospital • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:32 UTC
-
New drug shows promise in shrinking head and neck tumors before surgery
Disease control Recruiting nowThis phase II trial is testing whether the drug ivonescimab, given before surgery, can shrink tumors in people with stage II-IV head and neck cancer that can be removed. Ivonescimab is a type of antibody that helps the immune system fight cancer. The study will enroll 28 adults w…
Matched conditions: ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Supercharged immune cells take on Hard-to-Treat head and neck cancer
Disease control Recruiting nowThis early-stage trial tests a new therapy made from cord blood immune cells that are engineered to better target and attack head and neck cancer cells. Up to 33 patients with advanced disease that has not responded to standard treatments will receive these cells along with low-d…
Matched conditions: ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Morning vs. afternoon: can timing boost cancer immunotherapy?
Disease control Recruiting nowThis study looks at whether getting standard immunotherapy in the morning (before 11 am) or afternoon (after 12 pm) changes how well it fights advanced or metastatic solid tumors. Researchers think the body's internal clock (circadian rhythm) might affect immune activity. About 1…
Matched conditions: ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE4 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New cancer drug IACS-6274 enters early human testing
Disease control Recruiting nowThis early-phase trial is testing a new drug called IACS-6274, either alone or combined with other cancer drugs, in 54 adults with advanced solid tumors (such as melanoma, ovarian, or head and neck cancers). The main goal is to find the safest dose and understand side effects. Th…
Matched conditions: ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug cocktail targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new antibody called HMBD-001 combined with two existing cancer drugs (cetuximab and docetaxel) in people with advanced squamous cell cancers of the lung, head and neck, esophagus, cervix, or skin. The goal is to see if the combination is safe and can shrink tum…
Matched conditions: ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Hummingbird Bioscience • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
MRNA vaccine takes on Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early study tests a new mRNA vaccine (IL-22BP) for people with advanced solid tumors like sarcoma, head and neck cancer, or melanoma that have not responded to standard treatments. The vaccine is injected directly into tumors. Only 6 participants are enrolled to check safety…
Matched conditions: ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Xingchen Peng • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC